Relapsed or refractory multiple myeloma patients experience high response rates, overall survival with bortezomib-based therapy.
DLBCL and FL patients experience considerable economic burden during the first year after diagnosis.
Patients treated with anti–PD-1 or anti–PD-L1 inhibitors in clinical trials were successfully retreated with the inhibitors after discontinuing the treatment.
The combination of obinutuzumab and lenalidomide was found to be effective in relapsed or refractory follicular B-cell lymphoma.
A high level of resilience was associated with a better mental and physical health-related quality of life among patients with multiple myeloma.
The survival advantages associated with NCCN guideline–driven care were not realized in younger patients with stage II and stage III rectal cancer.
New data support PFS as a surrogate endpoint for OS in future trials evaluating chemoimmunotherapy in DLBCL.
In the DBL3001 trial, the combination of ibrutinib and R-CHOP was not superior to treatment with R-CHOP alone.
The inverse association between circulating DBP and risk of RCC support emerging evidence for an etiologic role of DBP in cancer.
A nested case-control study found that the association between obesity and RCC varies depending on subtype.